These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38116437)

  • 61. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Human Hsp90 cochaperones: perspectives on tissue-specific expression and identification of cochaperones with similar in vivo functions.
    Dean ME; Johnson JL
    Cell Stress Chaperones; 2021 Jan; 26(1):3-13. PubMed ID: 33037995
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effectiveness of hsp90 inhibitors as anti-cancer drugs.
    Xiao L; Lu X; Ruden DM
    Mini Rev Med Chem; 2006 Oct; 6(10):1137-43. PubMed ID: 17073714
    [TBL] [Abstract][Full Text] [Related]  

  • 64. HSP90: a rising star on the horizon of anticancer targets.
    Dai C; Whitesell L
    Future Oncol; 2005 Aug; 1(4):529-40. PubMed ID: 16556029
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Geldanamycin and its anti-cancer activities.
    Fukuyo Y; Hunt CR; Horikoshi N
    Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Chaperoning steroidal physiology: lessons from mouse genetic models of Hsp90 and its cochaperones.
    Sanchez ER
    Biochim Biophys Acta; 2012 Mar; 1823(3):722-9. PubMed ID: 22155719
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
    Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH
    Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Heat shock protein 90 from Escherichia coli collaborates with the DnaK chaperone system in client protein remodeling.
    Genest O; Hoskins JR; Camberg JL; Doyle SM; Wickner S
    Proc Natl Acad Sci U S A; 2011 May; 108(20):8206-11. PubMed ID: 21525416
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Disrupting progression of the yeast Hsp90 folding pathway at different transition points results in client-specific maturation defects.
    Hohrman K; Gonçalves D; Morano KA; Johnson JL
    Genetics; 2021 Mar; 217(3):. PubMed ID: 33789348
    [TBL] [Abstract][Full Text] [Related]  

  • 70. ATP-Driven Nonequilibrium Activation of Kinase Clients by the Molecular Chaperone Hsp90.
    Xu H
    Biophys J; 2020 Oct; 119(8):1538-1549. PubMed ID: 33038305
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions.
    Yun BG; Huang W; Leach N; Hartson SD; Matts RL
    Biochemistry; 2004 Jun; 43(25):8217-29. PubMed ID: 15209518
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Targeting Hsp90 for the treatment of cancer.
    Drysdale MJ; Brough PA; Massey A; Jensen MR; Schoepfer J
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):483-95. PubMed ID: 16889231
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.
    Chan CT; Reeves RE; Geller R; Yaghoubi SS; Hoehne A; Solow-Cordero DE; Chiosis G; Massoud TF; Paulmurugan R; Gambhir SS
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2476-85. PubMed ID: 22895790
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
    De Mattos-Arruda L; Cortes J
    Breast; 2012 Aug; 21(4):604-7. PubMed ID: 22560618
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
    Li L; Wang L; You QD; Xu XL
    J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
    Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
    [TBL] [Abstract][Full Text] [Related]  

  • 77. E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells.
    Samant RS; Clarke PA; Workman P
    Proc Natl Acad Sci U S A; 2014 May; 111(18):6834-9. PubMed ID: 24760825
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Effect of Heat Shock Protein 90 Inhibitor on Pain in Cancer Patients: A Systematic Review and Meta-Analysis.
    Miles VN; Patel RK; Smith AG; McCall RP; Wu J; Lei W
    Medicina (Kaunas); 2020 Dec; 57(1):. PubMed ID: 33374669
    [TBL] [Abstract][Full Text] [Related]  

  • 79. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
    Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Radiosynthesis, biological evaluation and preliminary microPET study of
    Kang J; Young Lee J; Taş İ; More KN; Kim H; Park JH; Chang DJ
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3658-3664. PubMed ID: 30528977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.